Immunotherapy of advanced gastric cancer: advances in monoclonal antibodies / 国际药学研究杂志

ABSTRACT

Gastric cancer is one of the common malignant tumors in China. Most gastric cancers are discovered at the late stage. Monoclonal antibody can inhibit and kill cancer cells specifically,with less toxic and side effects. Re- cently,monoclonal antibodies such as anti-epidermal growth factor receptor 1(EGFR1)antibody,anti-HER-2 antibody, anti-vascular endothelial growth factor(VEGF)antibody,anti-programmed death protein-1(PD-1)and anti-PD-L1 anti- body have been developed and applied. Monoclonal antibody therapy has become a hot spot in the immunotherapy of ad- vanced gastric cancer. Herein,the action mechanisms and clinical efficacy of various monoclonal antibodies for the treat- ment of advanced gastric cancer are reviewed,so as to provide a reference for future research,development and clinical application of monoclonal antibodies for the treatment of gastric cancer.